JP2016531913A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531913A5
JP2016531913A5 JP2016537782A JP2016537782A JP2016531913A5 JP 2016531913 A5 JP2016531913 A5 JP 2016531913A5 JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016531913 A5 JP2016531913 A5 JP 2016531913A5
Authority
JP
Japan
Prior art keywords
ketamine
tablet composition
gum
composition according
naket
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/052786 external-priority patent/WO2015031410A1/en
Publication of JP2016531913A publication Critical patent/JP2016531913A/ja
Publication of JP2016531913A5 publication Critical patent/JP2016531913A5/ja
Pending legal-status Critical Current

Links

JP2016537782A 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与 Pending JP2016531913A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869884P 2013-08-26 2013-08-26
US61/869,884 2013-08-26
US201462015513P 2014-06-22 2014-06-22
US62/015,513 2014-06-22
PCT/US2014/052786 WO2015031410A1 (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016717A Division JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Publications (2)

Publication Number Publication Date
JP2016531913A JP2016531913A (ja) 2016-10-13
JP2016531913A5 true JP2016531913A5 (https=) 2017-10-05

Family

ID=52587281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537782A Pending JP2016531913A (ja) 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Country Status (5)

Country Link
US (4) US9913803B2 (https=)
EP (2) EP3035918B1 (https=)
JP (2) JP2016531913A (https=)
CA (1) CA2922507C (https=)
WO (1) WO2015031410A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
DK3272338T3 (da) * 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
AU2015343083B2 (en) 2014-11-04 2020-07-23 Acadia Pharmaceuticals Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6696994B2 (ja) * 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2018191482A2 (en) * 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
EP3641742B1 (en) * 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
US10869838B2 (en) * 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー. 大うつ病性障害の処置方法
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
JP2023543211A (ja) * 2020-09-24 2023-10-13 ダグラス ファーマシューティカルズ エルティーディー. 徐放性医薬製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6492488B1 (en) * 1998-08-02 2002-12-10 Pmd Holdings Corp. Controlled release polyacrylic acid granules and a process for preparing the same
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
NZ537142A (en) * 2002-06-10 2008-01-31 Wyeth Corp Novel formate salt of O-desmethyl-venlafaxine
US20080027119A1 (en) * 2002-07-31 2008-01-31 Lippa Arnold S Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders
US20080176873A1 (en) * 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria
WO2008118785A2 (en) 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
EP2830604A4 (en) * 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
JP6374965B2 (ja) 2013-09-23 2018-08-15 コンヴィオン オサケユキチュアConvion Oy 高温電池システムのための再循環装置及び方法

Similar Documents

Publication Publication Date Title
JP2016531913A5 (https=)
Filous et al. Targeting astrocytes in CNS injury and disease: A translational research approach
JP2012193216A5 (https=)
PH12013500215B1 (en) Corticosteroids for the treatment of joint pain
RU2020127610A (ru) Нейроактивные стероиды, композиции и способы их применения
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
EP2911695C0 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE BY SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC TYPES OF NEURONS
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
JP2013535505A5 (https=)
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
JP2012046524A5 (https=)
WO2015118537A3 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
EA033054B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2015522522A5 (https=)
RU2016137292A (ru) Схема применения соединения fgf-18
JP2017507142A5 (https=)
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
JP2015522603A5 (https=)
JP2016515550A5 (https=)
JP2017531042A5 (https=)
RU2015146324A (ru) Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей
JP2015512948A5 (https=)
WO2014011949A3 (en) Neuroprotective cb2 receptor agonists